Diagnostic value of brain natriuretic peptide and β-endorphin plasma concentration changes in patients with acute left heart failure and atrial fibrillation

What Was Tested

Researchers studied BNP (Nesiritide) in this observational study publication.

This study aims to evaluate the diagnostic value of beta-endorphin (β-EP) and brain natriuretic peptid (BNP) plasma concentrations for the early diagnosis of acute left heart failure and atrial fibrillation.

Enzyme-linked immunosorbent assay was performed to detect the plasma concentration of β-EP and BNP in the treatment and control groups, and electrocardiogram targeting was performed to determine the left ventricular ejection fraction (LVEF).

Why It Was Studied

The diagnos stand was that of the Chinese guidelines for the diagnosis and treatment of heart failure.

Β-EP and BNP have high specificity and sensitivity for detecting early acute left heart failure and atrial fibrillation in patients, which is convenient, easy to perform, and suitable for clinical applications.

Who Took Part

According to the abstract, 45 patients were involved.

The age groups tagged for this paper are adults and middle-aged adults, both men and women.

A total of 45 patients were included.

These patients comprised 23 male and 22 female patients,and 20 healthy subjects who underwent physical examinations in the Outpatient Department during the same periodwere included and assigned to the control group.

What Was Measured

Topics PubMed links to this paper include Atrial Fibrillation, Biomarkers, Electrocardiography, Enzyme-Linked Immunosorbent Assay, Heart Failure, Natriuretic Peptide, Brain and ROC Curve.

What This Means in Plain Language

This is an observational study of BNP (Nesiritide) in 45 patients.

Results are reported in around 6 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2017 (Medicine), a journal based in United States.

More context: the BNP (Nesiritide) compound page, all human trials.